Literature DB >> 3262173

Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.

H Tsujihashi1, H Matsuda, S Uejima, T Akiyama, T Kurita.   

Abstract

Tissue infiltrating lymphocytes (TIL) in bladder tumors have been assumed to be an expression of local host resistance against the tumor. We investigated the functional activity of TIL compared to peripheral blood lymphocytes (PBL). Isolation of TIL was performed using the enzyme cocktail treatment with Ficoll-Hypaque discontinuous gradient centrifugation. Analysis of lymphocyte subsets by flow cytometry demonstrated Leu 4, 43.6% (T cells); Leu 10, 10.5% (B cells) and Leu 7, 13.1% (natural killer (NK) cells) in TIL. The cytotoxic activity of TIL and PBL was tested in a four hour 51Cr-release assay. Myeloid K562 cells (NK sensitive), HT 1197 (bladder tumor) and fresh bladder tumors were used as target cells. The spontaneous NK cell activity of PBL was 23.7%, whereas that of TIL was only 3.5%. However, in vitro culture with IL2 induced a significant augmentation of NK activity in TIL as well as in PBL. On the other hand, the spontaneous lymphokine activated killer cell (LAK) activity of PBL and TIL was very low. IL2-cultured PBL and TIL exhibited the highest levels of lysis against fresh bladder tumors. Unlike PBL, IL2-induced cytotoxicity of TIL against autologous bladder tumors was higher than that against allogenic bladder tumors. Immunomodulators OK432 and Il2 were injected intratumorally during endoscopy. Analysis of the lymphocyte subsets in TIL showed an increase of T and NK cells following immunomodulator injection. Endoscopic injection of immunomodulators into bladder tumors augmented NK cell functional activity in TIL as well as PBL. These findings suggest that local immunosurveillance is directed against bladder tumors. Further studies are required to understand more fully the local and systemic host immune responses in cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262173     DOI: 10.1016/s0022-5347(17)41851-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

2.  Analysis of tissue ABH antigens in superficial bladder tumours.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

3.  Tumor-infiltrating lymphocytes from nonrenal urological malignancies.

Authors:  G P Haas; D Solomon; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Authors:  Amanda J Vandeveer; Jonathan K Fallon; Robert Tighe; Helen Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Cancer Immunol Res       Date:  2016-02-26       Impact factor: 11.151

5.  Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.

Authors:  K Itoh; K Hayakawa; M A Salmeron; S S Legha; J L Murray; M Talpaz; C M Balch; D R Parkinson; K Lee; A A Zukiwski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Anti-tumor effect of intravesical instillation of OK432 against rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Urol Res       Date:  1990

7.  The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation.

Authors:  J Hu; J Kinn; A A Zirakzadeh; A Sherif; G Norstedt; A-C Wikström; O Winqvist
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 8.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26

9.  Clinical assessment of carcinoma in situ of the human urinary bladder.

Authors:  H Tsujihashi; A Nakanishi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

10.  Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction.

Authors:  J A Barbuto; W J Grimes; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.